Additional Topics:
Bronchiectasis and COPD
-
Bronchiectasis Care With BRINSUPRI: The First Approval in NCFB
on
Read more: Bronchiectasis Care With BRINSUPRI: The First Approval in NCFBJoin us to learn about bronchiectasis management! Bronchiectasis expert Diego Maselli, MD, FCCP, ATSF, covers an overview of the disease and discusses an approach to treating non-cystic fibrosis bronchiectasis, with a focus on targeted management. Dr. Maselli is a paid speaker. [41/50]
-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
Read more: Explore the Latest Developments in Bronchiectasis During ATS 2026 OrlandoIn August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone…
-
ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPD
on
Read more: ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPDRecent reports show that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, with 141,733 deaths related to the disease during that year. Additionally, treatments for the disease incur annual medical costs of approximately $24 billion for adults aged 45 and older. Spyridon Fortis, MD, PhD,…
Interstitial Lung Disease/Pulmonary Fibrosis (ILD/IPF)
-
A Landmark Moment: A Discussion on JASCAYD® (nerandomilast) tablets
on
Read more: A Landmark Moment: A Discussion on JASCAYD® (nerandomilast) tabletsPlease join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium. Click Here to learn more.
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
on
Read more: ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPFThe ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview…